Compare · GNLX vs LLY
GNLX vs LLY
Side-by-side comparison of Genelux Corporation (GNLX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNLX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 8344.8x GNLX ($128.2M).
- LLY has been more active in the news (19 items in the past 4 weeks vs 2 for GNLX).
- LLY has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Genelux Corporation
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $128.2M
- $1.07T
- 1M return
- -
- +17.48%
- 1Y return
- -
- +40.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 2
- 19
- Recent ratings
- 6
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest GNLX
- Head of Regulatory Smalling Ralph sold $563 worth of shares (192 units at $2.93), decreasing direct ownership by 0.28% to 67,611 units (SEC Form 4)
- Director Thomas John sold $29,801 worth of shares (10,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 472,784 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph sold $1,799 worth of shares (605 units at $2.97), decreasing direct ownership by 0.39% to 154,549 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,798 worth of shares (605 units at $2.97), decreasing direct ownership by 0.40% to 149,706 units (SEC Form 4)
- Head of Regulatory Smalling Ralph sold $804 worth of shares (270 units at $2.98), decreasing direct ownership by 0.40% to 67,803 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,226 worth of shares (2,798 units at $2.94), decreasing direct ownership by 0.52% to 532,051 units (SEC Form 4)
- Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- SEC Form DEFA14A filed by Genelux Corporation
- SEC Form DEF 14A filed by Genelux Corporation
Latest LLY
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio